Search Results for “diagnostic” – Page 62 – media

Ddu’s International Medical Exhibition Attendance Delivering High Results.

Ddu, the leading global pharmaceutical & medical device B2B online platform, is currently attending global exhibitions, leaving its footprints at multiple word-class medical trade shows in South Korea, India, Chongqing (China), Turkey and the United States.
- Source: Ddu
- 49,764
- April 9, 2018
Exhibitions & Activities medical device pharmaceutical
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna® (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
- Source: Novartis
- 631
- March 29, 2018
FDA New Approvals Ph+ CML-CP Tasigna®
Charity launches biometrics wristband project for autistic people

The North-West charity aims to build the world’s first autism assessment and diagnostic centre in Wirral, where biometric technology will be used to measure physiological properties of people with autism.
- Source: MedicalPlasticsNews
- 594
- March 29, 2018
autism digital health Researches wearables
Bayer announces completion of rolling submission of New Drug Application in the U.S. for larotrectinib for the treatment of TRK fusion cancer

Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO), a biopharmaceutical company based in Stamford, Connecticut (US), has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
- Source: investor.bayer.de
- 593
- March 28, 2018
FDA larotrectinib New Approvals NTRK
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced publication of an article that demonstrated the Company’s proprietary ADAPT Biotargeting System™ (ADAPT) significantly out-performed standard HER2 testing in predicting response to trastuzumab (Herceptin®) for breast cancer patients.
- Source: Carislifesciences
- 845
- March 27, 2018
breast cancer Researches trastuzumab
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA Priority Review designation; provides clinicians with pediatric-specific safety and clinical data Novartis continues commitment to people living with CML, including pediatric patients with this cancer
- Source: novartis
- 636
- March 26, 2018
chronic myeloid leukemia Clinical Trials FDA Tasigna®
Brain ‘Stethoscope’ Listens For Silent Seizures

Researchers have developed what they have dubbed a ‘brain stethoscope’, a device capable of turning EEG brain wave data into sound. The device is able to detect epileptic seizures that do not result in convulsions.
- Source: Neuroscience News
- 1,302
- March 23, 2018
medical device neuroscience Researches
New AI technique dramatically improves the quality of medical imaging

AUTOMAP offers a number of potential benefits for clinical care, even beyond producing high-quality images in less time with MRI or with lower doses with X-ray, CT and PET. Because of its processing speed, the technique could help in making real-time decisions about imaging protocols while the patient is in the scanner.
- Source: Artificial Intelligence Research
- 481
- March 22, 2018
AI imaging machine learning Researches
Preview — Global Pharmaceutical and Medical Device Exhibitions in the Second Quarter of 2018

Have you prepared for all the exhibitions you want to attend in the second quarter of 2018? Ddu, the leading global pharmaceutical & medical device B2B online platform, plans to attend a number of major international pharmaceutical and medical device exhibitions in the second quarter of this year. Here is a summary of each event:
- Source: Ddu
- 150,237
- March 16, 2018
Exhibitions & Activities medical device pharmaceutical
New guidelines recommend hysteroscopy test for heavy periods

More women in England and Wales are to be offered a test to better determine the causes of heavy menstrual bleeding, on updated guidelines from the National Institute for Health and Care Excellence.
- Source: pharmatimes
- 395
- March 16, 2018
Hysteroscopy menstrual bleeding Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.